Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Why a blend rather than two vials Combining both compounds in a single documented lot reduces preparation steps and variability between components in a research setting
However, existing studies have not confirmed any increase in cancer risk and in some cases, Epitalon appeared to reduce tumor incidence
BPC-157 and TB-500 remain on the FDA Category 2 'do not compound' list
A 2025 safety study confirmed that IV BPC-157 was well tolerated with no adverse events in healthy adults
US$ 20.91
US$ 22.85
US$ 26.77
